CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® in Children with Hereditary Angioedema
CSL Canada Announces First Canadian Patient Receives HEMGENIX® Hemophilia B Gene Therapy in Ontario, Canada
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Transition Metals Expands Gowganda Gold Project to 125 Square-kilometres in Ontario's Abitibi Greenstone Belt
